These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660 [TBL] [Abstract][Full Text] [Related]
5. Growth-hormone and prolactin excess. Colao A; Lombardi G Lancet; 1998 Oct; 352(9138):1455-61. PubMed ID: 9808008 [TBL] [Abstract][Full Text] [Related]
6. Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly. Sandler LM; Burrin JM; Joplin GF; Bloom SR Br Med J (Clin Res Ed); 1988 Mar; 296(6624):751-2. PubMed ID: 2894886 [No Abstract] [Full Text] [Related]
7. [Long-term treatment of acromegaly with a somatostatin analog]. Vest S Ugeskr Laeger; 1987 Aug; 149(34):2263. PubMed ID: 2897734 [No Abstract] [Full Text] [Related]
10. The therapeutic value of somatostatin and its analogues. Farooqi S; Bevan JS; Sheppard MC; Wass JA Pituitary; 1999 Jun; 2(1):79-88. PubMed ID: 11081176 [TBL] [Abstract][Full Text] [Related]
11. Pegvisomant Treatment in Acromegaly. Neggers SJ; Muhammad A; van der Lely AJ Neuroendocrinology; 2016; 103(1):59-65. PubMed ID: 25792221 [TBL] [Abstract][Full Text] [Related]
12. [Advancing acromegaly with low growth hormone levels. Influence of an analog of somatostatin administered in continuous subcutaneous infusion]. Leblanc H; Lebouc Y; Saltiel H; Thote A; Passa P Presse Med; 1988 Feb; 17(4):164. PubMed ID: 2894669 [No Abstract] [Full Text] [Related]
13. Long term treatment of acromegaly with a long acting analogue of somatostatin. Ch'ng LJ; Sandler LM; Kraenzlin ME; Burrin JM; Joplin GF; Bloom SR Br Med J (Clin Res Ed); 1985 Jan; 290(6464):284-5. PubMed ID: 2857104 [No Abstract] [Full Text] [Related]
14. Somatostatin analogs in the treatment of acromegaly: the choice is now possible. Chanson P Eur J Endocrinol; 2000 Nov; 143(5):573-5. PubMed ID: 11078979 [No Abstract] [Full Text] [Related]
15. Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome. Geffner ME; Nagel RA; Dietrich RB; Kaplan SA J Pediatr; 1987 Nov; 111(5):740-3. PubMed ID: 2889819 [No Abstract] [Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295 [TBL] [Abstract][Full Text] [Related]
17. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Colao A; Auriemma RS; Pivonello R Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466 [TBL] [Abstract][Full Text] [Related]
18. Acromegaly: a unique human headache model. Levy MJ; Bejon P; Barakat M; Goadsby PJ; Meeran K Headache; 2003; 43(7):794-7. PubMed ID: 12890136 [No Abstract] [Full Text] [Related]
19. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Neggers SJ; van der Lely AJ Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099 [TBL] [Abstract][Full Text] [Related]